Making the case against gene patents

Perspectives on Science

Volumn 23, Issue 1, 2015, Pages 106-145

  Simoncelli, Tania ^a   Park, Sandra S ^b  

^a White House   (United States)

^b American Civil Liberties Union Women s Rights Project   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84924023807     PISSN: 10636145     EISSN: 15309274     Source Type: Journal    
DOI: 10.1162/POSC_a_00161     Document Type: Article

References (74)

1. A. & P. Tea Co. v. Supermarket Equipment Corp. 1950. U.S. Supreme Court. 340 U.S. 147 (1950) (Douglas, J., concurring).
2. Abate, Tom. 2000. “Call It the Gene Rush—Patent Stakes Run High.” San Francisco Chronicle, 20 April, p. A8.
3. American Civil Liberties Union et al. 2013. Brief as Amici Curiae in Support of Defendants’ Opposition to Plaintiffs’ Motion for Preliminary Injunction, University of Utah Research Foundation v. Ambry Genetics Corp., 13-cv-640-RJS (D. Utah).
4. American College of Medical Genetics. 2000. Comment 32, 20 March. US Patent and Trademark Office. http://www. USPTO. gov/web/offices/com/sol/comments/utilguide/acmg.pdf.
5. American Fruit Growers, Inc. v. Brogdex Co. 1931. US Supreme Court. 283 U.S. 1 (1931). http://supreme.justia.com/cases/federal/us/283/1/ (accessed27 April 2014)
6. Arnold P’ship v. Dudas. 2004. U.S. Federal Circuit. 362 F. 3d 1338, 1340 (2004).
7. Ashcroft v. Free Speech Coalition. 2002. U.S. Supreme Court. 535U.S. 234 (2002).
8. Association for Molecular Pathology. 2000. Comment 36, 17March. US Patent and Trademark Office. http://www. USPTO. gov/web/offices/com/sol/comments/utilguide/amp.pdf.
9. Ass’n for Molecular Pathology v. Myriad Genetics, Inc. 2011. “Petition for aWrit of Certiorari,” 6 December. Supreme Court of the United States.
10. Ass’n for Molecular Pathology v. Myriad Genetics, Inc. 2012. US Supreme Court. 132 U.S. 1794 (2012).
11. Ass’n for Molecular Pathology v. U.S. Patent and Trademark Office. 2009. 669 F. Supp. 2d 365 (2009).
12. Ass’n for Molecular Pathology v. U.S. Patent and Trademark Office. 2010. 702 F. Supp. 2d 181 (2010).
13. Ass’n for Molecular Pathology v. U.S. Patent and Trademark Office. 2011. 653 F. 3d 1329 (2011).
14. Ass’n for Molecular Pathology v. U.S. Patent and Trademark Office. 2012. 689 F. 3d 1303 (2012).
15. Ass’n for Molecular Pathology v. Myriad Genetics, Inc. 2013. U.S. Supreme Court. 133 S. Ct. 2107 (2013).
16. Bilski v. Kappos. 2010. U.S. Supreme Court. 130 U. S. 3218 (2010). http://www.supremecourt.gov/opinions/09pdf/08-964.pdf (accessed 27 April 2014)
17. Cho, Mildred, S. Illangasekare, M. A. Weaver, D. G. Leonard, and J. F. Merz. 2003. “Effects of Patents and Licenses on the Provision of Clinical Genetic Testing Services.” Journal of Molecular Diagnostics 5 (1): 3–8.
18. Davies, Kevin and Michael White. 1995. Breakthrough: The Race to Find the Breast Cancer Gene. New York: John Wiley & Sons, Inc.
19. Diamond v. Chakrabarty. 1980. U.S. Supreme Court. 447 U.S. 303 (1980). https://supreme.justia.com/cases/federal/us/447/303/case.html.
20. Diamond v. Diehr. 1981. U.S. Supreme Court. 450 U.S. 175 (1981).
21. Eldred v. Ashcroft. 2003. U.S. Supreme Court. 537 U.S. 186, 219 (2003).
22. Epperson v. Arkansas. 1968. U.S. Supreme Court. 393 U.S. 97 (1968).
23. Federico, P. J. 1937. “Louis Pasteur’s Patents.” Science 86 (October 8): 327.
24. FunkBros. SeedCo. v. Kalo Co. 1948.U.S. Supreme Court. 333 U.S. 127 (1948).
25. Francione, Gary L. 1987. “Experimentation and the Marketplace Theory
26. of the First Amendment.” University of Penssylvania Law Review 136: 417–513.
27. Gottschalk v. Benson. 1972. U.S. Supreme Court. 409 U.S. 63 (1972).
28. Griswold v. Connecticut. 1965. U.S. Supreme Court. 381 U.S. 479, 482 (1965).
29. Harper & Row Publishers, Inc. v. Nation Enters. 1985. U.S. Supreme Court. 471 U.S. 539, 556 (1985).
30. Huang, Kenneth G. and Fiona E.Murray. 2009. “Does Patent Strategy Shape the Long-Run Supply of Public Knowledge? Evidence From Human Genetics.” Academy of Management Journal 52 (6): 1193.
31. In re: BRCA1– And BRCA2–Based Hereditary Cancer Test Patent Litigation, MDL No. 2510, 2014 WL 690559.
32. Institute for Intellectual Property & Information Law. 2011. University of Houston Law Center, Patstats.org, Full Calendar Year 2011 Report. http://www.patstats.org/2011_Full_Year_Report.html. (accessed 27 April 2014)
33. Jensen, Kyle and Fiona Murray. 2005. “Intellectual Property Landscape of the Human Genome.” Science 14: 239–40. http://www.sciencemag.org/content/310/5746/239.
34. Katyal, Neal. 2011. Oral Argument of Acting Solicitor General, Apr. 4, 2011, Ass’n. for Molecular Pathology v. U. S. Patent and Trademark Office. 653 F. 3d 1329 (2011).
35. Lab. Corp. v. Metabolite Labs. 2006. US Supreme Court. 548 U.S. 124, 126–27 (2006) (Breyer, J., dissenting) (dismissal of certiorari as improvidently granted).
36. Lee, Peter. 2013. “All Life is an Experiment’: Research Tool Patents, Epistemological Monopolies, and the First Amendment.” UC Davis Legal Studies Research Paper No. 348, August 23, 2013. http://papers.ssrn. com/sol3/papers.cfm?abstract_id=2315256.
37. Leonard, Debra G. B. 2002. “Medical Practice and Gene Patents: A Personal Perspective.” Academic Medicine Volume 77 (12, Part 2): 1388–1391.
38. Maxtone-Graham v. Burtchaell. 1986. 631 F. Supp. 1432 (S.D.N.Y. 1986).
39. Mayo Collaborative Servs. v. Prometheus Labs. 2010. US Supreme Court. 130 S.Ct. 3543 (2010).
40. Mayo Collaborative Servs. v. Prometheus Labs. 2012. US Supreme Court. 132 S.Ct. 1289 (2012).
41. Morgan, Paul F. and Bruce Stoner 2004. “Reexamination v. Litigation —Making Intelligent Decisions in Challenging Patent Validity.” Journal of the Patent and Trademark Office Society 86: 441–461.
42. Murray, John. 1999. “Owning Genes: Disputes Involving DNA Sequence Patents.” Chicago-Kent Law Review 75: 231–257.
43. Nat’l Breast Cancer Coalition. 2000. Comment 43. U.S. Patent and Trademark Office. http://www.USPTO.gov/web/offices/com/sol/comments/utilguide/nbcc.pdf.
44. National Advisory Council for Human Genome Research. 2000. NIH/Wylie Burke et al., Comment 42, Mar. 21. http://www.USPTO.gov/web/offices/com/sol/comments/utilguide/nih.pdf.
45. Nat’l Comprehensive Cancer Network. 2012. “NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast and Ovarian.” http://www.tri-kobe.org/nccn/guideline/gynecological/english/genetic_familial.pdf (accessed 27 April 2014)
46. O’Reilly v. Morse. 1853. U.S. Supreme Court. 56 U.S. 15 How. 62 62 (1853). http://supreme.justia.com/cases/federal/us/56/62/case.html (accessed 27 April 2014)
47. Palko v. Connecticut. 1937. U.S. Supreme Court. 302 U.S. 319 (1937).
48. Park, Sandra S. 2014. “Gene Patents and the Public Interest: Litigating Association for Molecular Pathology v. Myriad Genetics and Lessons Moving Forward.” North Carolina Journal of Law & Technology 15: 519–536.
49. Parke-Davis & Co. v. HK Mulford Co. 1911. 189 F. 95 (S.D.N.Y. 1911).
50. Parker v. Flook. 1978. US Supreme Court. 437 U.S. 584 (1978).
51. Parthasarathy, Shobita. 2007. Building Genetic Medicine: Breast Cancer, Technology, and the Comparative Politics of Health Care. Cambridge, Mass.: The MIT Press.
52. Pollack, Andrew. 2013. “After Patent Ruling, Availability of Gene Tests Could Broaden.” New York Times, 13 June.
53. Pollack, Andrew. 2011. “Despite Gene Patent Victory, Myriad Genetics Faces Challenges.” New York Times, 24 August, p. B1.
54. Prometheus Laboratories v. Mayo Collaborative Servs. 2009. 581 F. 3d 1336 (2009). Rabino, Isaac. 2001. “How Human Geneticists in US View Commercialization of the Human Genome Project.” Nature Genetics 29 (1): 15–16.
55. Robertson, John A. 1977. “The Scientist’s Right to Research: A Constitutional Analysis.” Southern California Law Review 51: 1203–1281.
56. Salinger v. Colting. 2009. 641 F. Supp. 2d 250, 255 (S.D.N.Y. 2009), rev’d on other grounds, 607 F. 3d 68 (2d Cir. 2010).
57. Scherer, Steven E. 2000. Comment 25, March 21. US Patent and Trademark Office. http://www.USPTO.gov/web/offices/com/sol/comments/utilguide/sscherer.pdf.
58. Schissel, Anna, Jon F. Merz, and Mildred K. Cho. 1999. “Survey Confirms Fears about Licensing of Genetic Tests.” Nature 402: 118.
59. Schmidt, Jason. 2000. “The Genome Warrior.” The New Yorker, 12 June. Secretary’s Advisory Committee on Genetics, Health, and Society (SACGHS). “Gene Patents and Licensing Practices and Their Impact on Patient Access to Genetic Tests.” April 2010. http://osp.od.nih.gov/sites/default/files/SACGHS_patents_report_2010.pdf
60. U. S. Patent No. 4,363,877 (issued Apr. 19, 1978).
61. U. S. Patent No. 5,654,155 (issued Feb. 12, 1996).
62. U. S. Patent No. 5,710,001 (issued Jan. 20, 1998).
63. U. S. Patent No. 5,753,441 (issued May 19, 1998).
64. U. S. Patent No. 5,809,999 (issued Sep. 22, 1998).
65. U. S. Patent No. 6,033,857 (issued Mar. 7, 2000).
66. United States Patent and Trademark Office. [1999] 2000. Revised Interim Utility Examination Guidelines published at 64 FR 71440, Dec. 21, 1999;
67. 1231 O. G. 136, Feb. 29, 2000, with a correction at 65 FR 3425, Jan. 21, 2000; 1231 O. G. 67, Feb. 15, 2000.
68. United States Patent and Trademark Office. 2001. Utility Examination Guidelines. 66 Fed. Reg. 1092. http://www.uspto.gov/web/offices/com/sol/notices/utilexmguide.pdf.
69. United States v. Reidel. 1971. U.S. Supreme Court. 402 U.S. 351, 355–56 (1971).
70. University of Washington. 2013. “UW Laboratory Medicine Clinical Test Information.” BROCA—Cancer Risk Panel, 1 October. http://web.labmed.washington.edu/tests/genetics/BROCA (accessed 27 April 2014)
71. Walsh, T., S. Casadei, K. H. Coats, E. Swisher, S. M. Stray, J. Higgins, K. C. Roach, J. Mandell, M. K. Lee, S. Ciernikova, L. Foretova, P. Soucek, M. C King. 2006. “Spectrum ofMutations in BRCA1, BRCA2, CHEK2, and TP53 in Families at High Risk of Breast Cancer.” Journal of the American Medical Association 295 (12): 1379–1388.
72. Walsh, T., M. K. Lee, S. Casadei, A. M. Thornton, S. M. Stray, C. Pennil, A.S. Nord, J. B. Mandell, E.M. Swisher, and M. C. King. 2010. “Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing,” Proceedings of the National Academy of Sciences 107 (28): 12629–12633.
73. Williams-Jones, Bryn. 2002. “History of a Gene Patent: Tracing the Development and Application of Commercial BRCATesting.” Health Law Journal 10: 123–146.
74. Yale Cancer Genetic Counseling. 2010. “Myriad Raises Price of BRCA Testing, Again.” Yale Cancer Genetic Counseling Blog, April 19. http://yalecancergeneticcounseling.blogspot.com/2010/04/myriad-raises-priceof-brca-testing.html. Perspectives on Science 145